COVID-19: Potential Repurposing Drugs

(E-pub Ahead of Print)

Author(s): Wattana Leowattana*

Journal Name: Infectious Disorders - Drug Targets
Formerly Current Drug Targets - Infectious Disorders

Become EABM
Become Reviewer
Call for Editor


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the most infectious diseases and caused coronavirus disease in 2019 (COVID-19). It has been widely spread worldwide and infected more than 28 million peoples in 215 countries, and more than 920,000 have now died from COVID-19. To date, no effective antiviral drugs or specific vaccines have been discovered yet. In this bewilderment, the potential therapeutic antiviral drug targets for the COVID-19 are repurposing to speed up the discovery of effective treatment. The most potential drug targets are continuously published, especially Favipiravir, Chloroquine, Hydroxychloroquine, and Remdesivir. Moreover, the antiviral target proteins and anti-host target proteins were reported continuously. This review summarized the current research studies of potential therapeutic drug targets being tested against the SARS-CoV-2. It will provide information relative to potential repurposing drugs to overcome the COVID-19.

Keywords: COVID-19, SARS-CoV-2, Repurposing Drugs, Chloroquine, Hydroxychloroquine, Favipiravir, Remdesivir

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 01 March, 2021
(E-pub Ahead of Print)
DOI: 10.2174/1871526521666210301143441
Price: $95

Article Metrics

PDF: 211